nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

18.03.2019 | Review – Cancer Research

The application of Apc^Min/+ mouse model in colorectal tumor researches

verfasst von: Junze Ren, Hua Sui, Fanfu Fang, Qi Li, Bai Li

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Apc^Min/+ mouse is an excellent animal model bearing multiple intestinal neoplasia, used to simulate human familial adenomatous polyposis and colorectal tumors. The key point of this model is the mutation of Apc gene, which is a significant tumor-suppressor gene in the Wnt signaling pathway. There are also some other possible mechanisms responsible for the development of colorectal tumors in the Apc^Min/+ mouse model, such as tumor-associated signaling pathways activation, the changes of tumor-related genes, and the involvement of some related proteins or molecules.

Methods

The relevant literatures about Apc^Min/+ mouse model from PUBMED databases are reviewed in this study.

Results

In recent years, increasing studies have focused on the application of Apc^Min/+ mouse model in colorectal tumor, trying to find effective therapeutic targets for further use.

Conclusion

This article will give a brief review on the related molecular mechanisms of the Apc^Min/+ mouse model and its application in colorectal tumor researches.

Altamemi I, Murphy EA, Catroppo JF, Zumbrun EE, Zhang J, McClellan JL, Singh UP, Nagarkatti PS, Nagarkatti M (2014) Role of microRNAs in resveratrol-mediated mitigation of colitis-associated tumorigenesis in Apc(Min/+) mice. J Pharmacol Exp Ther 350(1):99–109. https://doi.org/10.1124/jpet.114.213306 CrossRefPubMedPubMedCentral

An CH, Kim MS, Yoo NJ, Park SW, Lee SH (2011) Mutational and expressional analyses of ATG5, an autophagy-related gene, in gastrointestinal cancers. Pathol Res Pract 207(7):433–437. https://doi.org/10.1016/j.prp.2011.05.002 CrossRefPubMed

Arnason T, Pino MS, Yilmaz O, Kirley SD, Rueda BR, Chung DC, Zukerberg LR (2013) Cables1 is a tumor suppressor gene that regulates intestinal tumor progression in Apc(Min) mice. Cancer Biol Ther 14(7):672–678. https://doi.org/10.4161/cbt.25089 CrossRefPubMedPubMedCentral

Badenes M, Trindade A, Pissarra H, Lopes-da-Costa L, Duarte A (2017) Delta-like 4/Notch signaling promotes Apc (Min/+) tumor initiation through angiogenic and non-angiogenic related mechanisms. BMC Cancer 17(1):50. https://doi.org/10.1186/s12885-016-3036-0 CrossRefPubMedPubMedCentral

Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H (2009) Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457(7229):608–611. https://doi.org/10.1038/nature07602 CrossRefPubMed

Batlle E, Bacani J, Begthel H, Jonkheer S, Gregorieff A, van de Born M, Malats N, Sancho E, Boon E, Pawson T, Gallinger S, Pals S, Clevers H (2005) EphB receptor activity suppresses colorectal cancer progression. Nature 435(7045):1126–1130. https://doi.org/10.1038/nature03626 CrossRefPubMed

Benbrook DM, Guruswamy S, Wang Y, Sun Z, Mohammed A, Zhang Y, Li Q, Rao CV (2013) Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity. Cancer Prev Res (Phila) 6(9):908–916. https://doi.org/10.1158/1940-6207.CAPR-13-0171 CrossRef

Chae WJ, Bothwell AL (2011) IL-17F deficiency inhibits small intestinal tumorigenesis in Apc^Min/+ mice. Biochem Biophys Res Commun 414(1):31–36. https://doi.org/10.1016/j.bbrc.2011.09.016 CrossRefPubMed

Chae WJ, Bothwell AL (2015) Spontaneous intestinal tumorigenesis in Apc (/Min+) mice requires altered T cell development with IL-17A. J Immunol Res 2015:860106. https://doi.org/10.1155/2015/860106 CrossRefPubMedPubMedCentral

Chandrakesan P, Yao J, Qu D, May R, Weygant N, Ge Y, Ali N, Sureban SM, Gude M, Vega K, Bannerman-Menson E, Xia L, Bronze M, An G, Houchen CW (2017) Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells. Mol Cancer 16(1):30. https://doi.org/10.1186/s12943-017-0594-y CrossRefPubMedPubMedCentral

Chang WL, Jackson C, Riel S, Cooper HS, Devarajan K, Hensley HH, Zhou Y, Vanderveer LA, Nguyen MT, Clapper ML (2018) Differential preventive activity of sulindac and atorvastatin in Apc(+/Min-FCCC)mice with or without colorectal adenomas. Gut 67(7):1290–1298. https://doi.org/10.1136/gutjnl-2017-313942 CrossRefPubMed

Cheng L, Wang HP, Huang Q, Lai MD (2004) Microsatellite instability and relative gene expressions in sporadic and familial adenomatous polyposis adenomas. Yi Chuan 26(1):1–7PubMed

Cherukuri DP, Ishikawa TO, Chun P, Catapang A, Elashoff D, Grogan TR, Bugni J, Herschman HR (2014) Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, Apc^Min/+ mice. Mol Oncol 8(2):169–177. https://doi.org/10.1016/j.molonc.2013.10.009 CrossRefPubMed

Cheung AF, Carter AM, Kostova KK, Woodruff JF, Crowley D, Bronson RT, Haigis KM, Jacks T (2010) Complete deletion of Apc results in severe polyposis in mice. Oncogene 29(12):1857–1864. https://doi.org/10.1038/onc.2009.457 CrossRefPubMed

Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60(17):4705–4708PubMed

Clark AR, Lasa M (2003) Crosstalk between glucocorticoids and mitogen-activated protein kinase signalling pathways. Curr Opin Pharmacol 3(4):404–411CrossRefPubMed

DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ (1979) Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 76(5):2420–2424CrossRefPubMedPubMedCentral

Eads CA, Nickel AE, Laird PW (2002) Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic mice. Cancer Res 62(5):1296–1299PubMed

Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82(1):4–6CrossRefPubMed

Fujimoto K, Fujii G, Taguchi K, Yasuda K, Matsuo Y, Hashiyama A, Mutoh M, Tanaka H, Wada M (2015) Involvement of trefoil factor family 2 in the enlargement of intestinal tumors in Apc(Min/+) mice. Biochem Biophys Res Commun 463(4):859–863. https://doi.org/10.1016/j.bbrc.2015.06.025 CrossRefPubMed

Goodlad RA, Ryan AJ, Wedge SR, Pyrah IT, Alferez D, Poulsom R, Smith NR, Mandir N, Watkins AJ, Wilkinson RW (2006) Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the Apc^Min/+ mouse model of early intestinal cancer. Carcinogenesis 27(10):2133–2139. https://doi.org/10.1093/carcin/bgl113 CrossRefPubMed

Gregorieff A, Liu Y, Inanlou MR, Khomchuk Y, Wrana JL (2015) Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer. Nature 526(7575):715–718. https://doi.org/10.1038/nature15382 CrossRefPubMed

Grill JI, Herbst A, Brandl L, Kong L, Schneider MR, Kirchner T, Wolf E, Kolligs FT (2015) Inactivation of Itf2 promotes intestinal tumorigenesis in Apc(Min/+) mice. Biochem Biophys Res Commun 461(2):249–253. https://doi.org/10.1016/j.bbrc.2015.04.009 CrossRefPubMed

Gumireddy K, Li A, Kossenkov AV, Cai KQ, Liu Q, Yan J, Xu H, Showe L, Zhang L, Huang Q (2014) ID1 promotes breast cancer metastasis by S100A9 regulation. Mol Cancer Res 12(9):1334–1343. https://doi.org/10.1158/1541-7786.MCR-14-0049 CrossRefPubMedPubMedCentral

Hale VL, Chen J, Johnson S, Harrington SC, Yab TC, Smyrk TC, Nelson H, Boardman LA, Druliner BR, Levin TR, Rex DK, Ahnen DJ, Lance P, Ahlquist DA, Chia N (2017) Shifts in the fecal microbiota associated with adenomatous polyps. Cancer Epidemiol Biomark Prev 26(1):85–94. https://doi.org/10.1158/1055-9965.EPI-16-0337 CrossRef

Hamamoto T, Beppu H, Okada H, Kawabata M, Kitamura T, Miyazono K, Kato M (2002) Compound disruption of smad2 accelerates malignant progression of intestinal tumors in apc knockout mice. Cancer Res 62(20):5955–5961PubMed

Hamasaki H (2017) Exercise and gut microbiota: clinical implications for the feasibility of Tai Chi. J Integr Med 15(4):270–281. https://doi.org/10.1016/S2095-4964(17)60342-X CrossRefPubMed

Hawkes WC, Alkan Z (2011) Delayed cell cycle progression from SEPW1 depletion is p53- and p21-dependent in MCF-7 breast cancer cells. Biochem Biophys Res Commun 413(1):36–40. https://doi.org/10.1016/j.bbrc.2011.08.032 CrossRefPubMed

Hayes KS, Cliffe LJ, Bancroft AJ, Forman SP, Thompson S, Booth C, Grencis RK (2017) Chronic Trichuris muris infection causes neoplastic change in the intestine and exacerbates tumour formation in APC^min/+ mice. PLoS Negl Trop Dis 11(6):e0005708. https://doi.org/10.1371/journal.pntd.0005708 CrossRefPubMedPubMedCentral

He XY, Xiang C, Zhang CX, Xie YY, Chen L, Zhang GX, Lu Y, Liu G (2015) p53 in the myeloid lineage modulates an inflammatory microenvironment limiting initiation and invasion of intestinal tumors. Cell Rep 13(5):888–897. https://doi.org/10.1016/j.celrep.2015.09.045 CrossRefPubMed

Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253(5015):49–53CrossRefPubMed

Huderson AC, Myers JN, Niaz MS, Washington MK, Ramesh A (2013) Chemoprevention of benzo(a)pyrene-induced colon polyps in ApcMin mice by resveratrol. J Nutr Biochem 24(4):713–724. https://doi.org/10.1016/j.jnutbio.2012.04.005 CrossRefPubMed

Husoy T, Cruciani V, Knutsen HK, Mikalsen SO, Olstorn HB, Alexander J (2003) Cells heterozygous for the ApcMin mutation have decreased gap junctional intercellular communication and connexin43 level, and reduced microtubule polymerization. Carcinogenesis 24(4):643–650CrossRefPubMed

Jackstadt R, Sansom OJ (2016) Mouse models of intestinal cancer. J Pathol 238(2):141–151. https://doi.org/10.1002/path.4645 CrossRefPubMed

Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60(18):5040–5044PubMed

Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277–300. https://doi.org/10.3322/caac.20073 CrossRefPubMed

Jeyabalan J, Aqil F, Munagala R, Annamalai L, Vadhanam MV, Gupta RC (2014) Chemopreventive and therapeutic activity of dietary blueberry against estrogen-mediated breast cancer. J Agric Food Chem 62(18):3963–3971. https://doi.org/10.1021/jf403734j CrossRefPubMed

Ji Q, Luo YQ, Wang WH, Liu X, Li Q, Su SB (2016) Research advances in traditional Chinese medicine syndromes in cancer patients. J Integr Med 14(1):12–21. https://doi.org/10.1016/S2095-4964(16)60237-6 CrossRefPubMed

Jin D, Liu T, Dong W, Zhang Y, Wang S, Xie R, Wang B, Cao H (2017) Dietary feeding of freeze-dried whole cranberry inhibits intestinal tumor development in Apc(min/+) mice. Oncotarget 8(58):97787–97800. https://doi.org/10.18632/oncotarget.22081 CrossRefPubMedPubMedCentral

Kim YJ, Borsig L, Varki NM, Varki A (1998) P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA 95(16):9325–9330CrossRefPubMedPubMedCentral

Kolligs FT, Nieman MT, Winer I, Hu G, Van Mater D, Feng Y, Smith IM, Wu R, Zhai Y, Cho KR, Fearon ER (2002) ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell 1(2):145–155CrossRefPubMed

Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold GL, El-Omar EM, Brenner D, Fuchs CS, Meyerson M, Garrett WS (2013) Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14(2):207–215. https://doi.org/10.1016/j.chom.2013.07.007 CrossRefPubMedPubMedCentral

Kress M, May E, Cassingena R, May P (1979) Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J Virol 31(2):472–483PubMedPubMedCentral

Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278(5701):261–263CrossRefPubMed

Leko V, Park GJ, Lao U, Simon JA, Bedalov A (2013) Enterocyte-specific inactivation of SIRT1 reduces tumor load in the APC(+/min) mouse model. PLoS One 8(6):e66283. https://doi.org/10.1371/journal.pone.0066283 CrossRefPubMedPubMedCentral

Li X, Stevens PD, Liu J, Yang H, Wang W, Wang C, Zeng Z, Schmidt MD, Yang M, Lee EY, Gao T (2014) PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice. Gastroenterology 146(5):1301–1312 e1301–e1310. https://doi.org/10.1053/j.gastro.2014.02.003 CrossRefPubMed

Linzer DI, Levine AJ (1979) Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17(1):43–52CrossRefPubMed

Liu W, Chen L, Zhu J, Rodgers GP (2006) The glycoprotein hGC-1 binds to cadherin and lectins. Exp Cell Res 312(10):1785–1797. https://doi.org/10.1016/j.yexcr.2006.02.011 CrossRefPubMed

Liu W, Lee HW, Liu Y, Wang R, Rodgers GP (2010) Olfactomedin 4 is a novel target gene of retinoic acids and 5-aza-2′-deoxycytidine involved in human myeloid leukemia cell growth, differentiation, and apoptosis. Blood 116(23):4938–4947. https://doi.org/10.1182/blood-2009-10-246439 CrossRefPubMedPubMedCentral

Liu W, Yan M, Liu Y, McLeish KR, Coleman WG Jr, Rodgers GP (2012) Olfactomedin 4 inhibits cathepsin C-mediated protease activities, thereby modulating neutrophil killing of Staphylococcus aureus and Escherichia coli in mice. J Immunol 189(5):2460–2467. https://doi.org/10.4049/jimmunol.1103179 CrossRefPubMedPubMedCentral

Liu HP, Gao ZH, Cui SX, Wang Y, Li BY, Lou HX, Qu XJ (2013a) Chemoprevention of intestinal adenomatous polyposis by acetyl-11-keto-beta-boswellic acid in APC(Min/+) mice. Int J Cancer 132(11):2667–2681. https://doi.org/10.1002/ijc.27929 CrossRefPubMed

Liu W, Yan M, Sugui JA, Li H, Xu C, Joo J, Kwon-Chung KJ, Coleman WG, Rodgers GP (2013b) Olfm4 deletion enhances defense against Staphylococcus aureus in chronic granulomatous disease. J Clin Invest 123(9):3751–3755. https://doi.org/10.1172/JCI68453 CrossRefPubMedPubMedCentral

Liu V, Dietrich A, Kasparek MS, Benhaqi P, Schneider MR, Schemann M, Seeliger H, Kreis ME (2015) Extrinsic intestinal denervation modulates tumor development in the small intestine of Apc(Min/+) mice. J Exp Clin Cancer Res 34:39. https://doi.org/10.1186/s13046-015-0159-0 CrossRefPubMedPubMedCentral

Liu W, Li H, Hong SH, Piszczek GP, Chen W, Rodgers GP (2016) Olfactomedin 4 deletion induces colon adenocarcinoma in Apc(Min/+) mice. Oncogene 35(40):5237–5247. https://doi.org/10.1038/onc.2016.58 CrossRefPubMedPubMedCentral

Liu S, Tackmann NR, Yang J, Zhang Y (2017) Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis. Oncogene 36(10):1374–1383. https://doi.org/10.1038/onc.2016.301 CrossRefPubMed

Lopez-Arribillaga E, Rodilla V, Pellegrinet L, Guiu J, Iglesias M, Roman AC, Gutarra S, Gonzalez S, Munoz-Canoves P, Fernandez-Salguero P, Radtke F, Bigas A, Espinosa L (2015) Bmi1 regulates murine intestinal stem cell proliferation and self-renewal downstream of Notch. Development 142(1):41–50. https://doi.org/10.1242/dev.107714 CrossRefPubMed

Macias E, Jin A, Deisenroth C, Bhat K, Mao H, Lindstrom MS, Zhang Y (2010) An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein–Mdm2 interaction. Cancer Cell 18(3):231–243. https://doi.org/10.1016/j.ccr.2010.08.007 CrossRefPubMedPubMedCentral

McCart AE, Vickaryous NK, Silver A (2008) Apc mice: models, modifiers and mutants. Pathol Res Pract 204(7):479–490. https://doi.org/10.1016/j.prp.2008.03.004 CrossRefPubMed

McClellan JL, Steiner JL, Day SD, Enos RT, Davis MJ, Singh UP, Murphy EA (2014) Exercise effects on polyp burden and immune markers in the Apc^Min/+ mouse model of intestinal tumorigenesis. Int J Oncol 45(2):861–868. https://doi.org/10.3892/ijo.2014.2457 CrossRefPubMedPubMedCentral

McNally JB, Kirkpatrick ND, Hariri LP, Tumlinson AR, Besselsen DG, Gerner EW, Utzinger U, Barton JK (2006) Task-based imaging of colon cancer in the Apc(Min/+) mouse model. Appl Opt 45(13):3049–3062CrossRefPubMed

Melero JA, Stitt DT, Mangel WF, Carroll RB (1979) Identification of new polypeptide species (48-55K) immunoprecipitable by antiserum to purified large T antigen and present in SV40-infected and -transformed cells. Virology 93(2):466–480CrossRefPubMed

Menendez D, Inga A, Resnick MA (2009) The expanding universe of p53 targets. Nat Rev Cancer 9(10):724–737. https://doi.org/10.1038/nrc2730 CrossRefPubMed

Mohammed A, Janakiram NB, Li Q, Choi CI, Zhang Y, Steele VE, Rao CV (2011) Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention. Cancer Prev Res (Phila) 4(12):2015–2026. https://doi.org/10.1158/1940-6207.CAPR-11-0233 CrossRef

Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275(5307):1787–1790CrossRefPubMed

Moser AR, Pitot HC, Dove WF (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247(4940):322–324CrossRefPubMed

Munoz NM, Upton M, Rojas A, Washington MK, Lin L, Chytil A, Sozmen EG, Madison BB, Pozzi A, Moon RT, Moses HL, Grady WM (2006) Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res 66(20):9837–9844. https://doi.org/10.1158/0008-5472.CAN-06-0890 CrossRefPubMed

Nakamura Y, Arakawa H (2017) Discovery of Mieap-regulated mitochondrial quality control as a new function of tumor suppressor p53. Cancer Sci 108(5):809–817. https://doi.org/10.1111/cas.13208 CrossRefPubMedPubMedCentral

Nash GF, Turner LF, Scully MF, Kakkar AK (2002) Platelets and cancer. Lancet Oncol 3(7):425–430CrossRefPubMed

Newton R (2000) Molecular mechanisms of glucocorticoid action: what is important? Thorax 55(7):603–613CrossRefPubMedPubMedCentral

Norton JD (2000) ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 113(Pt 22):3897–3905PubMed

Pan P, Skaer CW, Wang HT, Stirdivant SM, Young MR, Oshima K, Stoner GD, Lechner JF, Huang YW, Wang LS (2015) Black raspberries suppress colonic adenoma development in Apc^Min/+ mice: relation to metabolite profiles. Carcinogenesis 36(10):1245–1253. https://doi.org/10.1093/carcin/bgv117 CrossRefPubMedPubMedCentral

Penny HL, Prestwood TR, Bhattacharya N, Sun F, Kenkel JA, Davidson MG, Shen L, Zuniga LA, Seeley ES, Pai R, Choi O, Tolentino L, Wang J, Napoli JL, Engleman EG (2016) Restoring retinoic acid attenuates intestinal inflammation and tumorigenesis in APC^Min/+ mice. Cancer Immunol Res 4(11):917–926. https://doi.org/10.1158/2326-6066.CIR-15-0038 CrossRefPubMedPubMedCentral

Qi C, Li B, Guo S, Wei B, Shao C, Li J, Yang Y, Zhang Q, Li J, He X, Wang L, Zhang Y (2015) P-selectin-mediated adhesion between platelets and tumor cells promotes intestinal tumorigenesis in Apc(Min/+) mice. Int J Biol Sci 11(6):679–687. https://doi.org/10.7150/ijbs.11589 CrossRefPubMedPubMedCentral

Rao CV (2004) Nitric oxide signaling in colon cancer chemoprevention. Mutat Res 555(1–2):107–119. https://doi.org/10.1016/j.mrfmmm.2004.05.022 CrossRefPubMed

Ray K (2011) Colorectal cancer: Fusobacterium nucleatum found in colon cancer tissue–could an infection cause colorectal cancer? Nat Rev Gastroenterol Hepatol 8(12):662. https://doi.org/10.1038/nrgastro.2011.208 CrossRefPubMed

Ruzinova MB, Benezra R (2003) Id proteins in development, cell cycle and cancer. Trends Cell Biol 13(8):410–418CrossRefPubMed

Sancho SC, Olson SL, Young So E, Shimomura K, Ouchi T, Preuss F (2016) Fibersol-2 induces apoptosis of Apc-deficient colorectal cancer (SW480) cells and decreases polyp formation in Apc MIN mice. Cancer Biol Ther 17(6):657–663. https://doi.org/10.1080/15384047.2016.1177685 CrossRefPubMedPubMedCentral

Sansom OJ, Berger J, Bishop SM, Hendrich B, Bird A, Clarke AR (2003) Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat Genet 34(2):145–147. https://doi.org/10.1038/ng1155 CrossRefPubMed

Sheng HQ, Chen J, Lai MD (2008) [Use of Apc(Min/+) mouse model in the studies of intestinal tumors]. Hereditas 30(3):277–282CrossRefPubMed

Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM (2003) Id proteins in cell growth and tumorigenesis. Cancer Cell 3(6):525–530CrossRefPubMed

Smith AE, Smith R, Paucha E (1979) Characterization of different tumor antigens present in cells transformed by simian virus 40. Cell 18(2):335–346CrossRefPubMed

Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, French PA, Dauerman HL, Becker RC, Platelet Colloquium P (2009) Platelet functions beyond hemostasis. J Thromb Haemost 7(11):1759–1766. https://doi.org/10.1111/j.1538-7836.2009.03586.x CrossRefPubMed

Sodir NM, Chen X, Park R, Nickel AE, Conti PS, Moats R, Bading JR, Shibata D, Laird PW (2006) Smad3 deficiency promotes tumorigenesis in the distal colon of Apc^Min/+ mice. Cancer Res 66(17):8430–8438. https://doi.org/10.1158/0008-5472.CAN-06-1437 CrossRefPubMed

Sohn KJ, Choi M, Song J, Chan S, Medline A, Gallinger S, Kim YI (2003) Msh2 deficiency enhances somatic Apc and p53 mutations in Apc^+/−Msh2^−/− mice. Carcinogenesis 24(2):217–224CrossRefPubMed

Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dove WF (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256(5057):668–670CrossRefPubMed

Suman S, Moon BH, Thakor H, Fornace AJ Jr, Datta K (2014) Wip1 abrogation decreases intestinal tumor frequency in APC(Min/+) mice irrespective of radiation quality. Radiat Res 182(3):345–349. https://doi.org/10.1667/RR13770.1 CrossRefPubMedPubMedCentral

Szekeres T, Saiko P, Fritzer-Szekeres M, Djavan B, Jager W (2011) Chemopreventive effects of resveratrol and resveratrol derivatives. Ann N Y Acad Sci 1215:89–95. https://doi.org/10.1111/j.1749-6632.2010.05864.x CrossRefPubMed

Tabrizian T, Wang D, Guan F, Hu Z, Beck AP, Delahaye F, Huffman DM (2017) Apc inactivation, but not obesity, synergizes with Pten deficiency to drive intestinal stem cell-derived tumorigenesis. Endocr Relat Cancer 24(6):253–265. https://doi.org/10.1530/ERC-16-0536 CrossRefPubMedPubMedCentral

Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM (1998) Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 92(5):645–656CrossRefPubMed

Tippin BL, Kwong AM, Inadomi MJ, Lee OJ, Park JM, Materi AM, Buslon VS, Lin AM, Kudo LC, Karsten SL, French SW, Narumiya S, Urade Y, Salido E, Lin HJ (2014) Intestinal tumor suppression in Apc^Min/+ mice by prostaglandin D2 receptor PTGDR. Cancer Med 3(4):1041–1051. https://doi.org/10.1002/cam4.251 CrossRefPubMedPubMedCentral

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262 CrossRefPubMed

Tsuneki M, Nakamura Y, Kinjo T, Nakanishi R, Arakawa H (2015) Mieap suppresses murine intestinal tumor via its mitochondrial quality control. Sci Rep 5:12472. https://doi.org/10.1038/srep12472 CrossRefPubMedPubMedCentral

VanDussen KL, Carulli AJ, Keeley TM, Patel SR, Puthoff BJ, Magness ST, Tran IT, Maillard I, Siebel C, Kolterud A, Grosse AS, Gumucio DL, Ernst SA, Tsai YH, Dempsey PJ, Samuelson LC (2012) Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. Development 139(3):488–497. https://doi.org/10.1242/dev.070763 CrossRefPubMedPubMedCentral

Varki NM, Varki A (2002) Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost 28(1):53–66. https://doi.org/10.1055/s-2002-20564 CrossRefPubMed

Wang H, Chakrabarty S (2003) Platelet-activating factor activates mitogen-activated protein kinases, inhibits proliferation, induces differentiation and suppresses the malignant phenotype of human colon carcinoma cells. Oncogene 22(14):2186–2191. https://doi.org/10.1038/sj.onc.1206348 CrossRefPubMed

Wang R, Wang Y, Gao Z, Qu X (2014) The comparative study of acetyl-11-keto-beta-boswellic acid (AKBA) and aspirin in the prevention of intestinal adenomatous polyposis in APC(Min/+) mice. Drug Discov Ther 8(1):25–32CrossRefPubMed

Wang L, Wang Y, Lu Y, Zhang Q, Qu X (2015) Heterozygous deletion of ATG5 in Apc(Min/+) mice promotes intestinal adenoma growth and enhances the antitumor efficacy of interferon-gamma. Cancer Biol Ther 16(3):383–391. https://doi.org/10.1080/15384047.2014.1002331 CrossRefPubMedPubMedCentral

Westbrook AM, Szakmary A, Schiestl RH (2016) Mouse models of intestinal inflammation and cancer. Arch Toxicol 90(9):2109–2130. https://doi.org/10.1007/s00204-016-1747-2 CrossRefPubMed

Xu C, Reichert EC, Nakano T, Lohse M, Gardner AA, Revelo MP, Topham MK, Stafforini DM (2013) Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc(Min/+) mice. Cancer Res 73(9):2806–2816. https://doi.org/10.1158/0008-5472.CAN-12-2374 CrossRefPubMedPubMedCentral

Yamada T, Mori Y, Hayashi R, Takada M, Ino Y, Naishiro Y, Kondo T, Hirohashi S (2003) Suppression of intestinal polyposis in Mdr1-deficient Apc^Min/+ mice. Cancer Res 63(5):895–901PubMed

Yamamoto Y, Sakamoto M, Fujii G, Tsuiji H, Kenetaka K, Asaka M, Hirohashi S (2003) Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology 37(3):528–533. https://doi.org/10.1053/jhep.2003.50029 CrossRefPubMed

Yaoita T, Sasaki Y, Yokozawa J, Sato T, Kanno N, Sakuta K, Yagi M, Yoshizawa K, Iwano D, Nagino K, Nomura E, Abe Y, Nishise S, Takeda H, Kawata S, Ueno Y (2015) Treatment with anti-interleukin-6 receptor antibody ameliorates intestinal polyposis in Apc(Min/+) mice under high-fat diet conditions. Tohoku J Exp Med 235(2):127–134. https://doi.org/10.1620/tjem.235.127 CrossRefPubMed

Yuan HQ, Kong F, Wang XL, Young CY, Hu XY, Lou HX (2008) Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochem Pharmacol 75(11):2112–2121. https://doi.org/10.1016/j.bcp.2008.03.005 CrossRefPubMed

Zhang LL, Wu JX (2006) DNA methylation: an epigenetic mechanism for tumorigenesis. Yi Chuan 28(7):880–885PubMed

Zhang MZ, Harris RC, McKanna JA (1999) Regulation of cyclooxygenase-2 (COX-2) in rat renal cortex by adrenal glucocorticoids and mineralocorticoids. Proc Natl Acad Sci USA 96(26):15280–15285CrossRefPubMedPubMedCentral

Zhang J, Liu WL, Tang DC, Chen L, Wang M, Pack SD, Zhuang Z, Rodgers GP (2002) Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene 283(1–2):83–93CrossRefPubMed

Zhang N, Subbaramaiah K, Yantiss RK, Zhou XK, Chin Y, Benezra R, Dannenberg AJ (2015) Id1 deficiency protects against tumor formation in Apc(Min/+) mice but not in a mouse model of colitis-associated colon cancer. Cancer Prev Res (Phila) 8(4):303–311. https://doi.org/10.1158/1940-6207.CAPR-14-0411 CrossRef

Zhao Y, Bao Q, Renner A, Camaj P, Eichhorn M, Ischenko I, Angele M, Kleespies A, Jauch KW, Bruns C (2011) Cancer stem cells and angiogenesis. Int J Dev Biol 55(4–5):477–482. https://doi.org/10.1387/ijdb.103225yz CrossRefPubMed

Zoller B, Holm J, Svensson P, Dahlback B (1996) Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost 75(2):270–274PubMed

Titel: The application of ApcMin/+ mouse model in colorectal tumor researches
verfasst von: Junze Ren
Hua Sui
Fanfu Fang
Qi Li
Bai Li
Publikationsdatum: 18.03.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-02883-6

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

The application of Apc^Min/+ mouse model in colorectal tumor researches

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1–NFATc2 fusion from Ewing sarcoma

Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer

Prognostic significance of metabolic parameters measured by 18F-FDG PET/CT in limited-stage small-cell lung carcinoma

Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia

Pathologic necrosis following neoadjuvant radiotherapy or chemoradiotherapy is prognostic of poor survival in soft tissue sarcoma

Impact of nodal status and treatment strategy on overall survival in advanced stage cervical cancer

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie